NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Aytu Biopharma, Inc. AYTU
18 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$66.4M
▲ 1.8% vs FY2023
EPS · FY24
—
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-58.1%
Net margin · FY24
-20.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 66.4M
Revenue, FY2024 · full 18-year series below
Revenue
Net income
The company lost 20 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-58.1%
Return on equity, FY2024
ROE
Operating margin-11.8%
Net margin-20.4%
Return on assets-11.2%
Each USD of equity lost 58 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+19.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−11.8%
+19.2%
+73.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 124.2M
total assets, end of FY2024
Total assetsUSD 124.2M
EquityUSD 19.0M
CashUSD 31.0M
Gross debtUSD 12.8M
Net debtUSD -18.2M
Current ratio1.26×
The company holds more cash than debt.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
EBITDA $B
−0.0
0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
−5.11
−74.01
−3.48
−3.01
−3.48
−15.31
−48.30
−323.70
−10.07
−0.80
−0.01
−0.03
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−58.1
−47.2
−40.8
−119.6
−50.1
−26.7
−264.5
−116.9
−319.6
−219.3
−73.6
−73.5
−1.2
·
·
−951.8
−255.4
−260.3
Shares out B
0.01
0.01
0.01
0.00
0.03
0.01
0.02
0.00
0.00
0.00
0.00
0.01
0.00
0.00
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed